CTCX (Carmell) Accounting Capitalization

Public company logo of Carmell (CTCX)

Carmell Corporation (CTCX) develops innovative tissue regeneration products. The price action shown below confirms stable sales driven by unique patents for plasma biomaterials, and the metric stands at -0.00. To reduce reliance on the aesthetic segment, the firm is introducing premium cosmetics. The high status of its developments and profit potential allow the company to recruit leading biologists to its staff.

CTCX - Carmell Therapeutics Book Capitalization over the range 02/21/2024 - 03/10/2025

CTCX (Carmell): analytical breakdowns and indicator data

- market value and analyst target forecast:
Stock Quotes Carmell Therapeutics|CTCX - Consensus Target
- business market valuation indicators:
Market Capitalization Carmell Corp.|CTCX - Total Company Value
- book capitalization indicators:
Share Book Value Carmell|CTCX - Book Capitalization|Market Value to Book Value carmellrx.com|CTCX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Carmell Corporation|CTCX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Carmell Corp.|CTCX - Company Debts|Debt to Book Value Carmell Corp.|CTCX - Company Long-Term Debts|Company Short-Term Debts Carmell|Intermediate Coverage Ratio carmellrx.com
- earnings and market ratios statistics:
CTCX - Company Net Income
Initial company analysis:Carmell Corporation
Mass-produced product of Carmell Corp.

The specifics of commercializing plasma products at Carmell Corporation (CTCX) under current low sales volumes create an excessive cost burden, which hinders the realization of operating leverage. By analyzing changes in the book value of equity on GURU.Markets, an investor assesses the difference between all assets and liabilities to determine the actual value of net assets, thereby protecting against overpaying for the asset and minimizing the risks of a deep drawdown.

Competitor analysis for Carmell Corporation

Ascendis (ASND) - Company Net Assets|MDGL (Madrigal Pharmaceuticals) - Company Net Assets|Accounting Capitalization CORT|Company Book Value Rhythm Pharmaceuticals, Inc.|Akero Therapeutics, Inc. - Net Asset Value|Book Capitalization MTSR|MLTX (MoonLake Corp) - Accounting Value of Company|Book Capitalization CRNX (Crinetics Pharmaceuticals)|Book Capitalization newamsterdampharma.com NAMS|SLNO - Company Book Value|Accounting Value of Company FOLD (Amicus Therapeutics Inc)|89bio Corp (ETNB) - Company Book Value|Company Net Assets Agios Corp|GPCR (Structure Therapeutics) - Book Capitalization|Book Capitalization mimedx.com|Company Net Assets RZLT (Rezolute)|LXRX (Lexicon Pharmaceuticals Inc) - Accounting Value of Company|Company Book Value MBX Bio MBX|ALT - Company Net Assets|Aardvark Therapeutics Inc - Book Capitalization|Total Stockholders' Equity sagimet.com|BIOA (BioAge) - Company Net Assets|BMEA: Total Net Assets|QNCX (Quince Therapeutics Inc) - Book Capitalization|Book Capitalization Fractyl Health, Inc|Book Capitalization VTVT|Company Book Value ATPC (agapeatpgroup.com)|Company Book Value Pluri PLUR|Synlogic Inc. (SYBX) - Total Stockholders' Equity|LPCN - Company Book Value|MTNB: Company Book Value|SPRB: Book Capitalization|GLTO - Book Valuation of Business|Company Book Value Lumos Pharma|Organovo Holdings (ONVO) - Book Valuation of Business|Company Book Value Radius Health (RDUS)